Benefit-Risk of Therapies for Relapsing-Remitting Multiple Sclerosis: Testing the Number Needed to Treat to Benefit (NNTB), Number Needed to Treat to Harm (NNTH) and the Likelihood to be Helped or Harmed (LHH): A Systematic Review and Meta-Analysis

Multiple Sclerosis

Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis

Ther Adv Neurol Disord.

Prosperini L, Kinkel RP, Miravalle AA, Iaffaldano P, Fantaccini S

doi: 10.1177/

SPECIAL REPORT

Multiple Sclerosis

Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis

Migraine and Headache

Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis

Cephalalgia

Drellia K, Kokoti L, Deligianni CI, Papadopoulos D, Mitsikostas DD

doi: 10.1177/0333102421989601

SPECIAL REPORT

Multiple Sclerosis

Vaccination Readiness in Multiple Sclerosis

Multiple Sclerosis

Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies

Mult Scler.

Van Wijmeersch B, Singer BA, Boster A, Broadley S, Fernández Ó, Freedman MS, Izquierdo G, Lycke J, Pozzilli C, Sharrack B, Steingo B, Wiendl H, Wray S, Ziemssen T, Chung L, Margolin DH, Thangavelu K, Vermersch P

doi: 10.1177/1352458519881759.

Psychosis and Schizophrenia

Attenuated psychotic symptom interventions in youth at risk of psychosis: A systematic review and meta-analysis

Early Interv Psychiatry.

Devoe DJ, Farris MS, Townes P, Addington J

doi: 10.1111/eip.12677.

Multiple Sclerosis

Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies

Eur J Neurol.

Havrdova E, Giovannoni G, Gold R, Fox RJ, Kappos L, Phillips JT, Okwuokenye M, Marantz JL

doi: 10.1111/ene.13272.

Aging and Cognitive FunctionsMultiple Sclerosis

Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study

Mult Scler.

Benedict RH, Cohan S, Lynch SG, Riester K, Wang P, Castro-Borrero W, Elkins J, Sabatella G

doi: 10.1177/1352458517707345.

Multiple Sclerosis

Daclizumab for the treatment of relapsing-remitting multiple sclerosis

Expert Opin Biol Ther

Herwerth M, Hemmer B

doi: 10.1080/14712598.2017.

Related content

Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis

Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis

Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis

Vaccination Readiness in Multiple Sclerosis

Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies

Attenuated psychotic symptom interventions in youth at risk of psychosis: A systematic review and meta-analysis

Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies

Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study

Daclizumab for the treatment of relapsing-remitting multiple sclerosis